Last reviewed · How we verify
Debrisoquin — Competitive Intelligence Brief
marketed
debrisoquine
Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Debrisoquin (Debrisoquine) — Hadassah Medical Organization.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Debrisoquin TARGET | Debrisoquine | Hadassah Medical Organization | marketed | debrisoquine | Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (debrisoquine class)
- Hadassah Medical Organization · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Debrisoquin CI watch — RSS
- Debrisoquin CI watch — Atom
- Debrisoquin CI watch — JSON
- Debrisoquin alone — RSS
- Whole debrisoquine class — RSS
Cite this brief
Drug Landscape (2026). Debrisoquin — Competitive Intelligence Brief. https://druglandscape.com/ci/debrisoquine. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab